Skip to main content

In Europe, QoL Is Not A Cancer Footnote


The European Medicines Agency (EMA) may soon elevate the importance of quality-of-life (QoL) outcomes in the assessment of new cancer therapies.
The EMA is creating a QoL appendix that will likely be added to its standard guideline for evaluating and approving cancer drugs and therapies, according to press materials.
Thus, treatment-related fatigue, nausea, sexual dysfunction, psychological problems, and other factors will become more important than they have been in terms of a therapy's approval.
This impending development was the subject of a session at the 3rd European Organization for Treatment and Research in Cancer (EORTC) conference, entitled International Quality of Life and Clinical Trials Conference, held in Brussels, Belgium.
"There is increasing recognition that health-related QoL is an effective and relevant measure with which to evaluate and monitor therapeutic outcomes. Health-related QoL measures may complement the range of traditional objective indicators, such as survival," said Daniel O'Connor, MB ChB, PhD, in a press statement. He is from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, and moderated a session at the conference.
QoL is one of a number of measures being considered for inclusion in the EMA's appendix to its "anticancer" guideline. Clinical trial design, statistical methodology, and patient-related outcome measures are also being considered. Work on the appendix is being done by an oncology working party on behalf of EMA's Committee for Medicinal Products for Human Use. It is expected that the appendix will be released for public consultation in 2013.
Another expert added context about the use of QoL as part of drug approval. "This new guidance will be increasingly important in this new era of anticancer medicines. Some new therapies that lead to limited improvements in survival can cause extensive problems with a patient's quality of life. Conversely, new therapies can cause less toxicity than older therapies since they have become more targeted," said Andrew Bottomley, PhD, from the EORTC, in a press statement.
Patient-Reported Outcomes Also in Focus
One of the shortcomings of QoL measures is that patient-reported outcomes are seen as "soft" data and are not valued as much as investigator assessments, said another presenter at the EORTC meeting, according to press materials. However, patient-reported outcomes will be more important in the future, predicted Lesley Fallowfield, PhD, from the University of Sussex in the United Kingdom.
Thirty years ago, a systematic review of literature on breast cancer and QoL would have yielded fewer than 20 citations; now, a search would yield more than a million, said Dr. Fallowfield. "While great strides are being made in the right direction, QoL is still not high enough on the priority lists of regulators and health authorities," she said.
Most new drugs have an excellent safety profile in clinical trials, but once in the real world, adverse effects reported by patients are different, she explained.
"Tamoxifen supposedly had few side effects when first approved, but its use commonly causes hot flushes, vaginal discharge, and even mood changes in patients. Likewise, the new generation aromatase inhibitors, such as letrozole, exemestane, and anastrozole, can cause joint pain and loss of libido. We need patients to be assessing these side effects in clinical trials and take account of these findings before a drug is approved. Although no one is going to die of a hot flush (apart from embarrassment), unresolved quality-of-life side effects lead many women to discontinue taking their otherwise life-saving drugs," Dr. Fallowfield said.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more